The diagnostic significance of circulating lncRNA ADAMTS9-AS2 tumor biomarker in non-small cell lung cancer among Egyptian population.

Abstract

BACKGROUND\nLong noncoding RNAs (LncRNA) ADAMTS9-AS2 was recognized as a novel tumor suppressor and it plays an important role in the initiation and progression of malignant behavior in human cancers, but its plasma expression and clinical value in patients with non-small cell lung cancer (NSCLC) remain unknown.\n\n\nOBJECTIVE\nWe aimed to analyze the diagnostic role of ADAMTS9-AS2 and CYFRA 21-1 in NSCLC.\n\n\nMATERIALS AND METHODS\nThis study included 80 control subjects, 80 patients with benign lung lesion and 80 NSCLC patients. The expression of ADAMTS9-AS2 in the tissue and plasma was detected by real time polymerase chain reaction. Serum CYFRA 21-1 was analyzed using ELISA kits.\n\n\nRESULTS\nIn comparison with benign lung lesion and controls, tissue and plasma ADAMTS9-AS2 expressions were significantly down-regulated in NSCLC (P < 0.001). Decreased ADAMTS9-AS2 expression was associated with TNM stages in NSCLC patients (P < 0.001). Up-regulation of CYFRA 21-1 was reported among NSCLC patients and it was associated with TNM staging. Tissue and plasma ADAMTS9-AS2 expression levels were the predicting factors for NSCLC and they both correlated negatively with CYFRA 21-1 levels. Plasma ADAMTS9-AS2 levels had a significant positive correlation with their tumor tissue levels. Plasma ADAMTS9-AS2 showed higher sensitivity (95%) and specificity (99.1%) in the diagnosis of NSCLC than CYFRA 21-1 (61.3% sensitivity and 60% specificity).\n\n\nCONCLUSIONS\nOur results suggested that decreased plasma ADAMTS9-AS2 expression might act as a novel non-invasive tumor biomarker in NSCLC diagnosis. Furthermore, plasma ADAMTS9-AS2 might predict aggressive tumor behavior.